Similarly, the treatment of db/db diabetic mice with PPARα agonists significantly reduces plasma insulin and insulin resistance, improves hyperglycemia, albuminuria, and kidney glomerular lesions, and causes a 50% reduction in FA oxidation, with a concomitant increase in glycolysis and glucose oxidation [376,377]. Here, PPARA is linked to Insulin resistance.